MOG (35-55): Gold-Standard Experimental Autoimmune Encephalomyelitis Inducer for MS Research

Executive Summary: MOG (35-55), a peptide derived from human myelin oligodendrocyte glycoprotein, is the most widely used agent for inducing experimental autoimmune encephalomyelitis (EAE) in murine models of multiple sclerosis (MS) (APExBIO). This peptide triggers robust T and B cell immune responses, recapitulating key pathological features of MS, including demyelination and relapsing-remitting neurological disease (Xu et al., 2025). In vitro, MOG (35-55) modulates protein concentrations and activates NADPH oxidase and MMP-9, aligning with oxidative stress and matrix remodeling pathways. The peptide's solubility profile and storage recommendations are critical for reproducible experimental outcomes. Recent mechanistic work links the immune activity of MOG (35-55) EAE models to the regulation of type I interferon signaling, providing insight into translational therapeutic strategies for MS (Xu et al., 2025).

Biological Rationale

MOG (35-55) is a synthetic peptide corresponding to amino acids 35–55 of the human myelin oligodendrocyte glycoprotein (MOG), a cell surface protein exclusively expressed in the central nervous system (CNS) (APExBIO). MOG is a member of the immunoglobulin superfamily, implicated in CNS myelin sheath integrity. Autoimmune targeting of MOG epitopes is central to the pathogenesis of MS, characterized by immune-mediated demyelination (MOG (35-55): Mechanistic Insights). The use of MOG (35-55) in rodents reliably induces EAE, recapitulating the immunopathology of human MS, including T and B cell infiltration, oligodendrocyte loss, and axonal damage. This makes it a gold standard for preclinical research on neuroinflammation and autoimmunity (Xu et al., 2025).

Mechanism of Action of MOG (35-55)

MOG (35-55) acts as an immunodominant epitope, efficiently presented by MHC class II molecules (notably HLA-DR2 in transgenic mice) to CD4+ T cells. Subcutaneous administration with complete Freund's adjuvant (CFA) triggers a strong autoreactive T and B cell response. This immune activation leads to the production of anti-MOG antibodies and pro-inflammatory cytokines, resulting in CNS demyelination and clinical EAE symptoms (Xu et al., 2025). In vitro, MOG (35-55) decreases total protein concentration (measured by BCA assay) and increases NADPH oxidase and MMP-9 activity, suggesting upregulation of oxidative stress and extracellular matrix degradation pathways. The peptide is biologically active in a dose-dependent manner, with higher concentrations correlating with more severe EAE phenotypes in murine models (APExBIO).

Evidence & Benchmarks

• MOG (35-55) reliably induces chronic, relapsing-remitting EAE in C57BL/6 and HLA-DR2-transgenic mice at doses of 50–150 μg (subcutaneous, with CFA) (DOI:10.1016/j.celrep.2025.116130).
• The peptide is soluble at ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO but insoluble in ethanol (manufacturer’s datasheet: APExBIO).
• Stock solutions should be prepared in sterile water at 0.50 mg/mL, warmed, and treated in an ultrasonic bath to enhance solubility (APExBIO).
• MOG (35-55) administration in mice results in weight loss and neurological deficits proportional to dose, with reproducible onset times (7–14 days post-immunization) (Optimizing Autoimmune Encephalomyelitis Models).
• In vitro exposure to MOG (35-55) increases NADPH oxidase and MMP-9 activity, indicating activation of oxidative and matrix remodeling pathways (DOI:10.1016/j.celrep.2025.116130).
• PARP7 inhibition restores STAT1/STAT2 stability and alleviates EAE symptoms in MOG (35-55) mouse models, highlighting the peptide’s role in dissecting interferon signaling (DOI:10.1016/j.celrep.2025.116130).

This article extends Mechanistic Insights by providing updated, benchmarked solubility and immunological response data, and bridges to translational interferon signaling research not covered in earlier reviews.

Applications, Limits & Misconceptions

MOG (35-55) is the reference peptide for establishing robust multiple sclerosis animal models, enabling reproducible induction of EAE for studies on neuroinflammation, autoimmunity, and therapeutic interventions (Beyond EAE Induction). It is widely used for:

• Screening candidate immunomodulatory or neuroprotective compounds.
• Dissecting T and B cell contributions to CNS autoimmunity.
• Modeling relapsing-remitting and chronic-progressive MS phenotypes.
• Studying molecular pathways, such as type I interferon signaling and the PARP7-STAT1/STAT2 axis (DOI:10.1016/j.celrep.2025.116130).

Common Pitfalls or Misconceptions

• Species Differences: MOG (35-55) does not induce EAE in all mouse strains; susceptibility depends on MHC haplotype (e.g., C57BL/6 respond robustly, BALB/c do not).
• Solvent Selection: The peptide is insoluble in ethanol; using inappropriate solvents reduces activity and reproducibility (APExBIO).
• Storage Instability: Stock solutions degrade at room temperature; storage at -20°C desiccated is essential.
• Translation Limits: While EAE recapitulates many MS features, it does not model all human disease complexities (e.g., progressive MS, remyelination failure).
• Overdose Effects: Doses >200 μg can cause non-specific toxicity and atypical disease phenotypes.

Workflow Integration & Parameters

MOG (35-55) is supplied by APExBIO (SKU A8306) as a lyophilized powder, with recommended preparation and handling protocols (product page):

• Reconstitution: Dissolve at ≥32.25 mg/mL in sterile water or ≥86 mg/mL in DMSO. Avoid ethanol.
• Stock Preparation: Use 0.50 mg/mL in sterile water, warming and using an ultrasonic bath if needed.
• Storage: Store desiccated at -20°C; use promptly to prevent degradation.
• Immunization: Administer 50–150 μg subcutaneously with CFA for EAE induction in susceptible mouse strains.
• In Vitro Assays: Apply dose-response protocols to study NADPH oxidase and MMP-9 activity changes.

Compared to Optimizing Autoimmune Encephalomyelitis Models, this article delivers more granular solubility and workflow data, facilitating reproducible assay setup and troubleshooting.

Conclusion & Outlook

MOG (35-55) remains the gold standard for experimental autoimmune encephalomyelitis research and is indispensable for mechanistic and translational MS studies. Its ability to recapitulate human MS immunopathology, combined with a well-characterized mechanism of action, underpins its continued utility in preclinical research. Ongoing advances—such as the elucidation of the PARP7-STAT1/STAT2 axis—further highlight the value of MOG (35-55) EAE models in bridging basic immunology and future therapeutic development (Xu et al., 2025). For additional strategic context, see Unraveling Immune Dynamics, which presents a systems-level view not covered here.